Deep Dive: Biotech stocks have been hit hard - here are ones analysts like best for a rebound

Deep Dive: Biotech stocks have been hit hard - here are ones analysts like best for a rebound


That spells opportunities for long-term investors, which Michael Brush explained while looking at stock prices relative to Jefferies analyst Michael Yee's estimated values of their product pipelines. You effectively can acquire product pipelines of great potential for next to nothing if you buy shares of Gilead Sciences So it may be useful to look at a summary of performance, valuations and analyst opinion for large-cap biotech companies.



from Biotech News